SLC29A4抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: 293T cells, Primary antibody: P08776(SLC29A4 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 second    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08776(SLC29A4 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The SLC29A4 antibody is a research tool designed to detect and study the solute carrier family 29 member 4 (SLC29A4), a transmembrane protein belonging to the equilibrative nucleoside transporter (ENT) family. SLC29A4. also known as ENT4. facilitates the bidirectional transport of nucleosides and nucleoside analogs across cellular membranes, playing roles in nucleotide salvage pathways, cellular signaling, and drug uptake. Unlike other ENT members, SLC29A4 exhibits unique pH-dependent activity, functioning optimally under acidic conditions, and demonstrates broad substrate specificity, including adenosine, monoamines, and certain antiviral/chemotherapeutic drugs.

Antibodies targeting SLC29A4 are widely used in applications such as Western blotting, immunohistochemistry, and immunofluorescence to investigate its expression, localization, and regulation in tissues. Research has linked SLC29A4 to physiological and pathological processes, including cardiovascular function (e.g., adenosine transport in cardiac cells), cancer progression (drug resistance mechanisms), and neurological disorders. Its expression in organs like the liver, placenta, and brain underscores its diverse roles in nutrient transport and xenobiotic disposition. Validating SLC29A4 antibodies requires careful consideration of specificity, as protein isoforms or post-translational modifications may affect detection. Current studies focus on its potential as a therapeutic target, particularly in oncology and metabolic diseases, driving demand for reliable antibodies to advance mechanistic and translational research.